QRON
Qrons Inc. [QRON] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
QRON Stock Summary
Top 10 Correlated Stocks
QRON
In the News
QRON Financial details
Company Rating
-
Market Cap
2.85M
Income
-1.31M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-2.38
Forward P/E
-
PEG
-13.45
P/S
-
P/B
-2.2
P/C
-
P/FCF
-48.98
Quick Ratio
0.01
Current Ratio
0.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
-45.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4233.33%
-
-
-
-
SMA20
-28.57%
SMA50
-37.5%
SMA100
-41.18%
Inst Own
-
Inst Trans
-
ROA
-18398%
ROE
98%
ROC
0.71%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.1557-0.745
52W High
-
52W Low
-
RSI
39.78
Rel Volume
9.79
Avg Volume
664
Volume
6.5K
Perf Week
29.71%
Perf Month
-36.61%
Perf Quarter
-48.04%
Perf Half Y
-47.47%
-
-
-
-
Beta
0.795
-
-
Volatility
0.03%, 0.03%
Prev Close
-29.57%
Price
0.09508
Change
-29.57%
Company Profile
- Volume Average 664
- Market Capitalization 2.85M
- Employee 2
- CEO Mr. Jonah Martin Meer
- Headquarters Long Island City,NY,US
- IPO Date 2017-09-12
-
Website
https://qrons.com 
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
